In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Criteo S.A. (NASDAQ:CRTO), Ferrari N.V. (NYSE:RACE), Freshpet, Inc. (NASDAQ:FRPT), ServiceMaster Global Holdings, Inc. (NYSE:SERV), CSG Systems International, Inc. (NASDAQ:CSGS), and Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CRTO DOWNLOAD: http://Capital-Review.com/register/?so=CRTO RACE DOWNLOAD: http://Capital-Review.com/register/?so=RACE FRPT DOWNLOAD: http://Capital-Review.com/register/?so=FRPT SERV DOWNLOAD: http://Capital-Review.com/register/?so=SERV CSGS DOWNLOAD: http://Capital-Review.com/register/?so=CSGS ARWR DOWNLOAD: http://Capital-Review.com/register/?so=ARWR

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Criteo S.A. (NASDAQ:CRTO), Ferrari N.V. (NYSE:RACE), Freshpet, Inc. (NASDAQ:FRPT), ServiceMaster Global Holdings, Inc. (NYSE:SERV), CSG Systems International, Inc. (NASDAQ:CSGS), and Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 25th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CRITEO S.A. (CRTO) REPORT OVERVIEW

Criteo S.A's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Criteo S.A reported revenue of $670.10MM vs $674.03MM (down 0.58%) and analysts estimated basic earnings per share $0.56 vs $0.82 (down 31.71%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Criteo S.A reported revenue of $2,300.31MM vs $2,296.69MM (up 0.16%) and analysts estimated basic earnings per share $1.33 vs $1.40 (down 5.00%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.34. The estimated EPS forecast for the next fiscal year is $1.69 and is expected to report on February 12th, 2020.

To read the full Criteo S.A. (CRTO) report, download it here: http://Capital-Review.com/register/?so=CRTO

-----------------------------------------

FERRARI N.V. (RACE) REPORT OVERVIEW

Ferrari N.V's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Ferrari N.V reported revenue of $963.30MM vs $992.48MM (down 2.94%) and analysts estimated basic earnings per share $1.17 vs $0.84 (up 39.02%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Ferrari N.V reported revenue of $4,039.40MM vs $3,862.11MM (up 4.59%) and analysts estimated basic earnings per share $4.91 vs $3.20 (up 53.59%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.96. The estimated EPS forecast for the next fiscal year is $4.43 and is expected to report on January 30th, 2020.

To read the full Ferrari N.V. (RACE) report, download it here: http://Capital-Review.com/register/?so=RACE

-----------------------------------------

FRESHPET, INC. (FRPT) REPORT OVERVIEW

Freshpet's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Freshpet reported revenue of $51.64MM vs $39.83MM (up 29.66%) and analysts estimated basic earnings per share $0.05 vs $0.06 (down 16.67%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Freshpet reported revenue of $193.24MM vs $152.36MM (up 26.83%) and analysts estimated basic earnings per share -$0.15 vs -$0.12. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is $0.57 and is expected to report on February 25th, 2020.

To read the full Freshpet, Inc. (FRPT) report, download it here: http://Capital-Review.com/register/?so=FRPT

-----------------------------------------

SERVICEMASTER GLOBAL HOLDINGS, INC. (SERV) REPORT OVERVIEW

ServiceMaster Global's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, ServiceMaster Global reported revenue of -$522.00MM vs -$492.00MM and basic earnings per share -$1.83 vs $2.26. For the twelve months ended December 31st, 2018 vs December 31st, 2017, ServiceMaster Global reported revenue of $1,900.00MM vs $1,755.00MM (up 8.26%) and analysts estimated basic earnings per share -$0.30 vs $3.79. Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.44. The estimated EPS forecast for the next fiscal year is $1.69 and is expected to report on February 25th, 2020.

To read the full ServiceMaster Global Holdings, Inc. (SERV) report, download it here: http://Capital-Review.com/register/?so=SERV

-----------------------------------------

CSG SYSTEMS INTERNATIONAL, INC. (CSGS) REPORT OVERVIEW

CSG Systems International's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, CSG Systems International reported revenue of $247.27MM vs $205.20MM (up 20.50%) and analysts estimated basic earnings per share $0.65 vs $0.45 (up 44.44%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, CSG Systems International reported revenue of $875.06MM vs $789.58MM (up 10.83%) and analysts estimated basic earnings per share $2.04 vs $1.89 (up 7.94%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.59. The estimated EPS forecast for the next fiscal year is $2.94 and is expected to report on February 5th, 2020.

To read the full CSG Systems International, Inc. (CSGS) report, download it here: http://Capital-Review.com/register/?so=CSGS

-----------------------------------------

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) REPORT OVERVIEW

Arrowhead Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Arrowhead Pharmaceuticals reported revenue of $34.66MM vs $3.51MM (up 887.46%) and analysts estimated basic earnings per share $0.13 vs -$0.18. For the twelve months ended September 30th, 2018 vs September 30th, 2017, Arrowhead Pharmaceuticals reported revenue of $16.14MM vs $31.41MM (down 48.60%) and analysts estimated basic earnings per share -$0.65 vs -$0.47. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.18. The estimated EPS forecast for the next fiscal year is -$0.24 and is expected to report on December 10th, 2019.

To read the full Arrowhead Pharmaceuticals, Inc. (ARWR) report, download it here: http://Capital-Review.com/register/?so=ARWR

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Nicole Garrens, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Arrowhead Pharmaceuticals Charts.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Arrowhead Pharmaceuticals Charts.